Background: Guidelines recommend neoadjuvant systemic therapy (NST) as the preferred treatment approach for stage II–III triple-negative breast cancer (TNBC), an aggressive form of breast cancer (BC) that lacks specific therapeutic targets. This study primarily aimed to assess the NST adoption among stage II–III TNBC patients in Greece under real-world conditions during the pre-immunotherapy era. Methods: This multicenter, observational, retrospective chart review included 230 female patients (≥18 years) with early-stage or locally advanced TNBC across 10 public and private BC reference centers over 6.5 years. Data included demographics and clinical characteristics at diagnosis, treatment details, clinical outcomes, and survival status. Descriptive statistics followed by uni/multivariate analyses were performed. Survival outcomes were assessed using survival analysis methods. Results: Women with stage II (67.4%) or stage III (32.6%) TNBC were included, with a median age of 53.1 years (range 23.9–84.1). Patients received NST [113 (49.1%)] and non-NST [117 (50.9%)]. NST utilization was significantly associated with larger tumor size andBRCA1/2testing and status. Overall, 43.9% underwentBRCA1/2testing, and 32.7% of those were positive for aBRCA1/2mutation. More than half of the patients (n= 61) achieved pathological complete response (pCR) following NST. Event rates were lower with NST (16.8%) versus without (24.8%). Utilization increased over time, peaking at 63.5% in 2020–2022. Conclusions: NST use showed moderate uptake with notable practice variations, emphasizing the need for multidisciplinary strategies to improve guideline adherence. Over half achieved pCR post-NST, setting a benchmark for TNBC care. Ongoing real-world monitoring is vital to guide long-term outcomes.
背景：指南推荐新辅助全身治疗（NST）作为II-III期三阴性乳腺癌（TNBC）的首选治疗方案，这是一种缺乏特异性治疗靶点的侵袭性乳腺癌。本研究主要旨在评估免疫治疗时代前，希腊II-III期TNBC患者在真实世界条件下接受NST的情况。方法：这项多中心、观察性、回顾性病历审查研究纳入了来自10个公立和私立乳腺癌参考中心、为期6.5年内的230例早期或局部晚期TNBC女性患者（年龄≥18岁）。数据包括诊断时的人口统计学和临床特征、治疗细节、临床结局和生存状态。进行了描述性统计及单/多变量分析。使用生存分析方法评估生存结局。结果：研究纳入了II期（67.4%）或III期（32.6%）TNBC女性患者，中位年龄为53.1岁（范围23.9–84.1）。患者接受了NST [113例（49.1%）] 和非NST [117例（50.9%）] 治疗。NST的使用与较大的肿瘤体积以及BRCA1/2检测和状态显著相关。总体而言，43.9%的患者接受了BRCA1/2检测，其中32.7%检测出BRCA1/2突变阳性。超过一半的患者（n=61）在NST后达到病理学完全缓解（pCR）。接受NST治疗的患者事件发生率（16.8%）低于未接受者（24.8%）。NST的使用率随时间推移而增加，在2020–2022年达到峰值（63.5%）。结论：NST的使用率呈中等水平，且存在显著的实践差异，这强调了需要多学科策略以提高指南依从性。超过一半的患者在NST后达到pCR，为TNBC的诊疗设立了基准。持续的真实世界监测对于指导长期结局至关重要。
肿瘤(癌症)患者之家